RNA therapeutics

Beyond RNA interference and antisense oligonucleotides

Ryszard Kole, Adrian R. Krainer, Sidney Altman

Research output: Contribution to journalReview article

594 Citations (Scopus)

Abstract

Here, we discuss three RNA-based therapeutic technologies exploiting various oligonucleotides that bind to RNA by base pairing in a sequence-specific manner yet have different mechanisms of action and effects. RNA interference and antisense oligonucleotides downregulate gene expression by inducing enzyme-dependent degradation of targeted mRNA. Steric-blocking oligonucleotides block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this mechanism, steric-blocking oligonucleotides can redirect alternative splicing, repair defective RNA, restore protein production or downregulate gene expression. Moreover, they can be extensively chemically modified to acquire more drug-like properties. The ability of RNA-blocking oligonucleotides to restore gene function makes them best suited for the treatment of genetic disorders. Positive results from clinical trials for the treatment of Duchenne muscular dystrophy show that this technology is close to achieving its clinical potential.

Original languageEnglish (US)
Pages (from-to)125-140
Number of pages16
JournalNature Reviews Drug Discovery
Volume11
Issue number2
DOIs
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

Antisense Oligonucleotides
RNA Interference
Oligonucleotides
RNA
Down-Regulation
Technology
Therapeutics
Gene Expression
Inborn Genetic Diseases
Duchenne Muscular Dystrophy
RNA Precursors
RNA Stability
Alternative Splicing
Base Pairing
Clinical Trials
Messenger RNA
Enzymes
Pharmaceutical Preparations
Genes
Proteins

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

RNA therapeutics : Beyond RNA interference and antisense oligonucleotides. / Kole, Ryszard; Krainer, Adrian R.; Altman, Sidney.

In: Nature Reviews Drug Discovery, Vol. 11, No. 2, 02.2012, p. 125-140.

Research output: Contribution to journalReview article

Kole, Ryszard ; Krainer, Adrian R. ; Altman, Sidney. / RNA therapeutics : Beyond RNA interference and antisense oligonucleotides. In: Nature Reviews Drug Discovery. 2012 ; Vol. 11, No. 2. pp. 125-140.
@article{fe4a4d507b18432eb58d87fe1510de69,
title = "RNA therapeutics: Beyond RNA interference and antisense oligonucleotides",
abstract = "Here, we discuss three RNA-based therapeutic technologies exploiting various oligonucleotides that bind to RNA by base pairing in a sequence-specific manner yet have different mechanisms of action and effects. RNA interference and antisense oligonucleotides downregulate gene expression by inducing enzyme-dependent degradation of targeted mRNA. Steric-blocking oligonucleotides block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this mechanism, steric-blocking oligonucleotides can redirect alternative splicing, repair defective RNA, restore protein production or downregulate gene expression. Moreover, they can be extensively chemically modified to acquire more drug-like properties. The ability of RNA-blocking oligonucleotides to restore gene function makes them best suited for the treatment of genetic disorders. Positive results from clinical trials for the treatment of Duchenne muscular dystrophy show that this technology is close to achieving its clinical potential.",
author = "Ryszard Kole and Krainer, {Adrian R.} and Sidney Altman",
year = "2012",
month = "2",
doi = "10.1038/nrd3625",
language = "English (US)",
volume = "11",
pages = "125--140",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - RNA therapeutics

T2 - Beyond RNA interference and antisense oligonucleotides

AU - Kole, Ryszard

AU - Krainer, Adrian R.

AU - Altman, Sidney

PY - 2012/2

Y1 - 2012/2

N2 - Here, we discuss three RNA-based therapeutic technologies exploiting various oligonucleotides that bind to RNA by base pairing in a sequence-specific manner yet have different mechanisms of action and effects. RNA interference and antisense oligonucleotides downregulate gene expression by inducing enzyme-dependent degradation of targeted mRNA. Steric-blocking oligonucleotides block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this mechanism, steric-blocking oligonucleotides can redirect alternative splicing, repair defective RNA, restore protein production or downregulate gene expression. Moreover, they can be extensively chemically modified to acquire more drug-like properties. The ability of RNA-blocking oligonucleotides to restore gene function makes them best suited for the treatment of genetic disorders. Positive results from clinical trials for the treatment of Duchenne muscular dystrophy show that this technology is close to achieving its clinical potential.

AB - Here, we discuss three RNA-based therapeutic technologies exploiting various oligonucleotides that bind to RNA by base pairing in a sequence-specific manner yet have different mechanisms of action and effects. RNA interference and antisense oligonucleotides downregulate gene expression by inducing enzyme-dependent degradation of targeted mRNA. Steric-blocking oligonucleotides block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this mechanism, steric-blocking oligonucleotides can redirect alternative splicing, repair defective RNA, restore protein production or downregulate gene expression. Moreover, they can be extensively chemically modified to acquire more drug-like properties. The ability of RNA-blocking oligonucleotides to restore gene function makes them best suited for the treatment of genetic disorders. Positive results from clinical trials for the treatment of Duchenne muscular dystrophy show that this technology is close to achieving its clinical potential.

UR - http://www.scopus.com/inward/record.url?scp=84856431819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856431819&partnerID=8YFLogxK

U2 - 10.1038/nrd3625

DO - 10.1038/nrd3625

M3 - Review article

VL - 11

SP - 125

EP - 140

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 2

ER -